Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by destruction of normal epithelial structure, proliferation of fibroblasts, and deposition of connective-tissue matrix proteins. Most patients experience a relentless progression to respiratory failure and death. Recent progress in dissecting key molecular mechanisms involved in disease progression has set the stage for implementation of novel therapies that prevent epithelial cell death, inhibit matrix deposition and deter mesenchymal cell proliferation. We have established with our reported observations and preliminary studies that low concentration inhaled CO provides protection in a murine model of bleomycin-induced lung fibrosis by targeting multiple molecular pathways relevant to the pathogenesis of IPF. Hypothesis: Inhaled low concentration carbon monoxide will slow or arrest the progression of lung fibrosis in patients with IPF. We will test the hypothesis by addressing the following specific aims:
Specific Aim #1 : To investigate whether, in IPF patients, 3 months of therapy with low dose inhaled CO results in a relative decrease in peripheral blood levels of MMP7 and stability in secondary indicators of disease progression.
Specific Aim #2 : To investigate the potential role of an IPF specific peripheral blood mononuclear gene expression signature to predict rates of disease progression and determine responsiveness to inhaled CO. Our goal is to study the use of low-dose inhaled CO as a therapeutic agent to treat IPF in humans. For this purpose we have assembled a remarkable group of basic and clinical researchers with expertise in the pathogenesis of IPF, CO biology, biomarker development, large-scale genomics and IPF clinical trials to investigate the effectiveness of a novel inhaled therapy in this devastating disease. Our ancillary proposals will clarify mechanisms of action of CO and validate a peripheral blood genomic signature capable of predicting individual response to CO treatment. The successful completion of this study will provide the basis for the design of a more definitive phase III clinical trial of low dose inhaled CO in IPF.

Public Health Relevance

This clinical trial will test our hypothesis that low-dose inhaled carbon monoxide will slow disease progression in IPF patients. We have assembled a group of researchers with expertise in the pathogenesis of IPF, CO biology, biomarker development, large-scale genomics and IPF clinical trials to investigate the effectiveness of a novel inhaled therapy in this devastating disease. Successful completion of this study will provide the basis for the design of a more definitive phase III clinical trial of low dose inhaled CO in IPF.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HL105371-02
Application #
8149936
Study Section
Special Emphasis Panel (ZHL1-CSR-H (S1))
Program Officer
Eu, Jerry Pc
Project Start
2010-09-24
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
2
Fiscal Year
2012
Total Cost
$1,900,200
Indirect Cost
$308,908
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Stout-Delgado, Heather W; Cho, Soo Jung; Chu, Sarah G et al. (2016) Age-Dependent Susceptibility to Pulmonary Fibrosis Is Associated with NLRP3 Inflammasome Activation. Am J Respir Cell Mol Biol 55:252-63
Araki, Tetsuro; Nishino, Mizuki; Gao, Wei et al. (2016) Normal thymus in adults: appearance on CT and associations with age, sex, BMI and smoking. Eur Radiol 26:15-24
Doyle, Tracy J; Patel, Avignat S; Hatabu, Hiroto et al. (2015) Detection of Rheumatoid Arthritis-Interstitial Lung Disease Is Enhanced by Serum Biomarkers. Am J Respir Crit Care Med 191:1403-12
Eickelberg, Oliver; Hunninghake, Gary M (2015) A first glimpse at the early origins of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 191:366-8
Kliment, Corrine R; Araki, Tetsuro; Doyle, Tracy J et al. (2015) A comparison of visual and quantitative methods to identify interstitial lung abnormalities. BMC Pulm Med 15:134
Rosas, Ivan O; Kaminski, Naftali (2015) Update in diffuse parenchymal lung disease, 2013. Am J Respir Crit Care Med 191:270-4
Araki, Tetsuro; Nishino, Mizuki; Gao, Wei et al. (2015) Pulmonary cysts identified on chest CT: are they part of aging change or of clinical significance? Thorax 70:1156-62
Chen, Juan; Doyle, Tracy J; Liu, Yongliang et al. (2015) Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol 67:28-38
George, Gautam; Rosas, Ivan O; Cui, Ye et al. (2015) Short telomeres, telomeropathy, and subclinical extrapulmonary organ damage in patients with interstitial lung disease. Chest 147:1549-57
Araki, Tetsuro; Nishino, Mizuki; Zazueta, Oscar E et al. (2015) Paraseptal emphysema: Prevalence and distribution on CT and association with interstitial lung abnormalities. Eur J Radiol 84:1413-8

Showing the most recent 10 out of 16 publications